Senti Biosciences to present at Synthetic Biology: Engineering, Evolution, & Design Conference.
ByAinvest
Tuesday, Jun 24, 2025 8:49 am ET1min read
LU--
The SEED Conference, established in 2014, is a premier technical event for synthetic biology professionals, attracting over 5,000 attendees since its inception. The conference serves as a platform for sharing research, networking, and discussing advances in synthetic biology [2].
Senti Bio is developing next-generation cell and gene therapies using its proprietary Gene Circuit platform. The company aims to engineer Gene Circuits into medicines with enhanced precision and control, specifically targeting cancer cells while sparing healthy cells. The company's pipeline includes cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications [1].
The presentation by Timothy Lu at the SEED Conference will highlight the potential of logic-gated cells in addressing the grand challenge of tumor-specific therapies. The company's Gene Circuits have shown preclinical success in both NK and T cells, and the company is exploring their potential in other modalities and diseases outside of oncology [1].
The SEED Conference is expected to provide a valuable opportunity for Senti Bio to share its innovative work, network with industry leaders, and gain insights into the latest advancements in synthetic biology [2].
References:
[1] https://www.globenewswire.com/news-release/2025/06/24/3104254/0/en/Senti-Bio-to-Present-at-the-2025-Synthetic-Biology-Engineering-Evolution-Design-SEED-Conference.html
[2] https://www.stocktitan.net/news/SNTI/senti-bio-to-present-at-the-2025-synthetic-biology-engineering-0uosxt1f3o50.html
SNTI--
TX--
Senti Biosciences will present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference. Timothy Lu, MD, PhD, Co-Founder and CEO, will present on "Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated Cells." The conference is being held in Houston, TX from June 23-26, 2025.
Senti Biosciences, Inc. (Nasdaq: SNTI), a clinical-stage biotechnology company, will present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference in Houston, TX, from June 23-26, 2025. The company's Co-Founder and CEO, Timothy Lu, MD, PhD, will present on "Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated Cells" on June 24, 2025, at 1:20 PM CT [1].The SEED Conference, established in 2014, is a premier technical event for synthetic biology professionals, attracting over 5,000 attendees since its inception. The conference serves as a platform for sharing research, networking, and discussing advances in synthetic biology [2].
Senti Bio is developing next-generation cell and gene therapies using its proprietary Gene Circuit platform. The company aims to engineer Gene Circuits into medicines with enhanced precision and control, specifically targeting cancer cells while sparing healthy cells. The company's pipeline includes cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications [1].
The presentation by Timothy Lu at the SEED Conference will highlight the potential of logic-gated cells in addressing the grand challenge of tumor-specific therapies. The company's Gene Circuits have shown preclinical success in both NK and T cells, and the company is exploring their potential in other modalities and diseases outside of oncology [1].
The SEED Conference is expected to provide a valuable opportunity for Senti Bio to share its innovative work, network with industry leaders, and gain insights into the latest advancements in synthetic biology [2].
References:
[1] https://www.globenewswire.com/news-release/2025/06/24/3104254/0/en/Senti-Bio-to-Present-at-the-2025-Synthetic-Biology-Engineering-Evolution-Design-SEED-Conference.html
[2] https://www.stocktitan.net/news/SNTI/senti-bio-to-present-at-the-2025-synthetic-biology-engineering-0uosxt1f3o50.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet